Table 5. Primary and main secondary endpoints, RS population

Figure 5. Kaplan Meier survival graphs for hospitalisation for worsening heart failure, RS

Figure 6. Kaplan-Meier survival curves for death due to heart failure, RS

The incidence of the secondary composite endpoint (cardiovascular death, hospitalisation for worsening heart failure or hospitalisation for non-fatal myocardial infarction) was 25.5% in the ivabradine group compared with 30.0% in the placebo group. This corresponded to an 18% relative risk reduction and was found to be statistically significant (hazard ratio 0.82, 95% CI [0.74, 0.89], p<0.0001).